Novochizol™ technology quantitatively transforms single linear chitosan molecules into uniformly sized nanoparticles that can be used alone, as emulsifiers or carriers of active ingredients.
Novochizol™ overcomes the limitations of chitosan, enhances its existing beneficial properties and displays new characteristics:
- Formulation of all API classes: small molecules, peptides, nucleic acids, proteins, viruses and cells.
- Low viscosity solutions/suspensions under all conditions
- Administration-targeted drug release, without systemic distribution
- Customizable sustained release properties
- Slow biodegradation and physical robustness
- Intracellular delivery of active ingredients, including proteins.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Route De L'ile-Au-Bois, 1a,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.novochizol.ch
- HQ
- Monthey , Valais
Novochizol Sa Questions
Novochizol Sa's website is http://www.novochizol.ch
Novochizol Sa's LinkedIn profile is https://ch.linkedin.com/company/novochizol
Novochizol Sa has
5 employees.
View email and phone details for 5
employees at Novochizol Sa.
Novochizol Sa's industry is
Biotechnology Research
Novochizol Sa's top competitors are
Haya Therapeutics,
Wama Diagnostics (Switzerland) Sa,
Immunskills Sa,
Orio Therapeutics,
Fluosphera,
Rem Analytics,
Arcoscreen,
Limula,
Bioark,
Ceidos.
Novochizol Sa's categories are Biotechnology Research
Novochizol Sa's founding year is 2021
